Metraipolis › archive › dc_77fb27d6beb2
Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients — Europe PMC PMID:41410871
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41410871
- DOI
- 10.1007/s00262-[numero omesso]-6
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T13:52:55.223Z
- SHA-256 of the archived text
0fd894989fa24c7f26ad5de9d802c593964081e83465cc1af4fedcfcf86b43fa- Stable URL of this page
https://metraipolis.com/documento/dc_77fb27d6beb2
How to cite
Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients — Europe PMC PMID:41410871 — Europe PMC (en), https://europepmc.org/article/MED/41410871 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_77fb27d6beb2 (Metraipolis archive dc_77fb27d6beb2, sha256 0fd894989fa24c7f26ad5de9d802c593964081e83465cc1af4fedcfcf86b43fa)
BibTeX
@misc{dc77fb27d6beb2,
title = {Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients — Europe PMC PMID:41410871},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41410871},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_77fb27d6beb2; sha256 0fd894989fa24c7f26ad5de9d802c593964081e83465cc1af4fedcfcf86b43fa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41410871. Agents can read the archived copy with the MCP tool read_document.